VolitionRx — Update 1 April 2016

VolitionRx (NYSE: VNRX)

Last close As at 27/03/2024

USD0.74

−0.01 (−0.93%)

Market capitalisation

USD62m

More on this equity

Research: Healthcare

VolitionRx — Update 1 April 2016

VolitionRx

Analyst avatar placeholder

Written by

volition01

Healthcare

VolitionRx

Closing in on commercialization

Quarterly update

Healthcare equipment & services

1 April 2016

Price

US$3.55

Market cap

US$82m

Net cash ($m) at December 2015

5.9

Shares in issue

23.1m

Free float

77%

Code

VNRX

Primary exchange

NYSEMKT

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(3)

(21.1)

(13.6)

Rel (local)

(9)

(21.7)

(13.3)

52-week high/low

US$5.2

US$3

Business description

VolitionRx is a Belgium-based diagnostics company focused on developing blood-based cancer diagnostics based on its proprietary NuQ technology. Its lead program is in colorectal cancer, which may enter the European market in 2016.

Next events

Prostate cancer data

H116

FDA feedback on 510(k) pathway

H216

Preliminary data from 14,000-person CRC trial

H216

Analysts

Maxim Jacobs

+1 646 653 7027

Nathaniel Calloway

+1 646 653 7036

VolitionRx is a research client of Edison Investment Research Limited

VolitionRx announced a new commercialization strategy for the US with its FY15 results. The company will seek a 510(k) approval in the US as an intermediate step to eventual PMA approval. This will allow for a quicker commercial launch of the NuQ colorectal test in the US, but would limit its marketing to “informing” a physician’s diagnosis instead of being a definitive diagnostic tool. The nearest-term revenues are in Europe, where a CE-mark approval and commercial launch are slated for late 2016.

Year end

Revenue ($m)

PBT*
($m)

EPS*
($)

DPS
($)

P/E
(x)

Yield
(%)

12/14

0.0

(8.4)

(0.62)

0.0

N/A

N/A

12/15

0.0

(9.7)

(0.54)

0.0

N/A

N/A

1216e

0.8

(13.9)

(0.59)

0.0

N/A

N/A

12/17e

2.2

(18.1)

(0.74)

0.0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

A stepwise approval process

VolitionRx will be seeking US approval for the NuQ colorectal cancer test via a staggered process in which the initial CLIA waivered NuQ colorectal test is supplemented with a 510(k) marketing authorization. The company predicts that the 510(k) trial will require a fraction of the total patients needed for a PMA approval (eg 500 vs 10,000) and significantly less time (six months). The company plans to initiate the 510(k) trial by the end of 2016 and the PMA trial shortly after.

New NuQ applications

The company released new data built on existing results demonstrating a best-in-class non-invasive test for colorectal adenomas (polyps), and using an optimized NuQ panel improved sensitivity of the test to 75% (78% specificity). In another trial the company was able to detect the rare lung disorder idiopathic pulmonary fibrosis with 86% sensitivity (80% specificity). This marks the first use of NuQ for a non-cancer related disorder, and suggests potential for other indications.

2015 results: Better cash, cost control than expected

VolitionRx reported Q415 and year end results, which showed better cost control (approximately $1m less cash used in operations than our estimates) and a better cash ending balance ($5.9m vs our estimate of $3.7m) than we predicted. The company still expects a CE mark and initial European launch in late 2016.

Valuation: $231m or $10.00 per basic share

We have increased our valuation to $231m from $197m, but with a decrease in the per share value to $10.00 per basic share ($8.58 diluted) from $10.90 ($8.86 diluted), due to an increase in shares following the March 2016 capital raise. The increase in valuation is predominantly due to rolling over our NPVs to 2016. The company should have cash in the range of $15-18m at the end of Q116, but it will need some $50m to reach profitability (down from previous estimate of $120m).

On track to NuQ launch: Europe 2016, US 2017?

VolitionRx is a diagnostics company that has developed an array of blood-based tests called NuQ, which detect cell-free nucleosomes in the blood. Nucleosomes are units of packaged DNA, and when cells die, they can be released into the bloodstream. Changes in the quantity or structure of these nucleosomes are correlated with various disorders including cancer. The company is using this technology to develop blood-based diagnostic tests for cancer using a combination of multiple NuQ tests in parallel. Their lead program is a NuQ panel for colorectal cancer (CRC) intended as a replacement for the fecal immunochemical test (FIT) and fecal occluded blood test (FOBT). The ability to use blood and the simplicity of the technology needed to run the test could allow NuQ to be integrated into pre-existing blood testing protocols. The company is initially targeting approval and commercialization in Europe and expects a CE mark and marketing to begin in late 2016 for the CRC test. The goal in Europe is to leverage the simplicity and low cost of the NuQ CRC test to seek approval from country-wide medical policy authorities.

The 510(k) strategy

VolitionRx announced for the first time a detailed regulatory and commercial strategy for the US on the most recent earnings call and in company filings. The plan is to expand the marketing authorization by seeking 510(k) clearance before the more rigorous PMA. In the US there are multiple tiers of regulatory clearance needed for different levels of marketing claims. First, any test may receive a waiver to be run in a CLIA (Clinical Laboratory Improvement Act) certified lab as long as there is not a substantial risk of error from running the test. The data from the test can be provided to the ordering physician, but marketing claims cannot be made regarding its efficacy at diagnosing a disease. Essentially a CLIA waiver will get the NuQ test on the market as fast as possible but the company cannot make any claims of efficacy.

The important aspect that was added in the most recent company guidance was the plan to seek near-term clearance via the 510(k) pathway. Diagnostics approved via this pathway are so-called “class II” tests, and their interpretation must pose at most a moderate impact to human health. Functionally this means that the company will be able to make claims for the use of NuQ panels under the umbrella that they are part of a physician’s overall assessment. Although the company has not received specific guidance from the FDA, clearances under this scheme could require trials with less than 1,000 patients. Adding this stage to the commercial rollout of the NuQ CRC test will get it into the hands of physicians and generating revenue sooner than previous plans with little overhead cost. The company is targeting trials with approximately 500 patients with a cost in the low single-digit millions per indication, contingent on FDA guidance. The company aims to meet with the FDA and initiate a 510(k) trial for CRC in 2016. The 510(k) application process has a quick review cycle, with a 90-day target turnaround. With all these factors in mind, there is the potential for a commercialization of the NuQ colorectal test in late 2017 in the US.

In the longer term, the company will be seeking a “class III” designation for tests whose interpretation poses a significant risk to heath and require submission of a PMA. This would allow claims that a NuQ panel is sufficient to diagnose a disease. A trial for PMA approval could require 10,000 or more patients, and the FDA requires that these tests are accurate and do not produce an excessive number of alarming false positives, necessitating a high specificity. However, these trials can be run concurrently with 510(k) enabling trials, and therefore the timeline to full marketing approval has not changed. The company plans on meeting with the FDA in 2016 to discuss paths forward for a PMA-enabling trial for CRC.

Clinical update

The company announced in February 2016 that it had competed an exploratory trial to detect pre-cancerous colorectal adenomas (polyps) at Hvidovre Hospital and the University of Copenhagen. The double-blind prospective trial included 430 patients who presented with symptoms or were high risk for CRC. The patients received a panel of five NuQ assays and their results were age-adjusted. Although previous CRC trials had accurately detected adenomas (63% sensitivity at 78% specificity), this was the first trial in which the NuQ panel was specifically tailored to detect adenomas. The result was that this panel accurately detected 75% of adenomas (at 78% specificity) in the background presence of 88 patients with stage I and II CRC.

These results improve on the already best-in-class sensitivity for non-invasive detection of colorectal adenomas (Exhibit 1). Because the presence of adenomas is a risk factor for developing CRC, this test may be used in the future to identify patients where increased surveillance is needed. The main factor limiting the potential utility of this test is the high number of false positives (22%), which could pose a risk of compelling a large number of unnecessary follow-up procedures such as colonoscopies. This risk could potentially be limited by accurate diagnosis and differentiation of patients with CRC who need follow-up over watchful waiting. Regardless, this will allow a degree of screening and stratification of at-risk individuals that simply is not possible with currently approved technology.

Exhibit 1: Adenoma detection sensitivity

Source: VolitioRx, Epigenomics, Exact Sciences, Applied Proteomics. Note: FOBT = fecal occult blood test, FIT = fecal immunochemical test.

VolitionRx also released results from a preliminary trial done in collaboration with Liège University Hospital in Belgium in which a NuQ panel was used to identify patients with Idiopathic Pulmonary Fibrosis (IPF). IPF is a rare, difficult to diagnose and ultimately fatal lung condition of unknown origin, in which accumulation of scar tissue occludes the microvasculature and air passages in the lung. There are an estimated 5m cases of IPF worldwide.1

  Raghu G, et al. (2011) An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 183:788–824.

The study used blood samples collected from 78 individuals (21 non-treated IPF patients, 27 treated IPF patients, 30 healthy volunteers). 86% of the non-treated IPF patients were correctly identified in the study with a specificity of 80%. The number of treated-IPF patients identified was not released, but it is a safe assumption that the detection rate was lower due to less cell death during treatment.

Although these results pose the possibility of further developing a NuQ panel of tests for IPF in the future, the most significant feature of this study is that it is the first study to not specifically target cancer (or dysplasia in the case of colorectal adenomas). This proof of concept opens the possibility that NuQ tests could be optimized for a variety of different disorders. Nucleosomes detected by NuQ are released into the bloodstream following cell death and any disorder that increases the rate of cell death will produce a signal that is identifiable by NuQ. However, the test will have particular utility in disorders that are characterized by an alteration in normal chromosomal expression patterns. The modification in the nucleosomes that causes these patterns can be identified with a panel of NuQ tests, leading to a higher level of specificity. Both cancer and fibrosis fall into this category, as do some degenerative and inflammatory disorders.

The company also has three near-term clinical readouts for prostate cancer, although at an earlier phase than other programs. We currently do not include the prostate cancer program in our valuation due to the lack of current clinical data, but this may change with the upcoming results from two clinical trials expected in H116. However, we believe that the bar for prostate cancer detection is higher than other programs due to the widespread prevalence of PSA (prostate specific antigen) testing.

Valuation

We have increased our valuation to $231m from $197m, although this represents a decrease in the per share value to $10.00 per basic share ($8.58 per diluted share) from $10.90/share ($8.86) due to dilution from the March 2016 equity offering. The largest factor in increasing our total firm value was rolling over our NPVs to 2016. We have integrated the new US 510(k) commercialization plan into our model by increasing R&D spending for individual US programs by approximately $5m each to account for the new trial, coupled with an earlier commercial launch. The net effect of these adjustments is small, the primary benefit being a hedge on failure of the PMA application. We expect to make adjustments to this portion of our model following the company’s forthcoming discussions with the FDA about the pathway.

We also expect to make changes to our valuation with upcoming clinical trial results, notably the prostate cancer trials, because if they significantly outperform PSA testing, we would include them in our future valuations.

We currently predict Q116 net cash at $16.6m, but we expect to adjust this for variation in operational costs for the quarter.

Exhibit 2: Valuation of VolitionRx

Product

Main Indication

Status

Prob. of commercial success

Launch year

Peak sales ($m)

Patent protection

Economics

rNPV ($m)

NuQ

Colorectal

Development

30%

2016

$404

2034

56% peak margin

$168

 

Lung

Development

30%

2018

$145

2034

61% peak margin

$38

Pancreatic

Development

30%

2018

$37

2034

58% peak margin

$9

Total

 

 

 

 

 

 

 

$214

Cash and cash equivalents (Q116 est.) ($m)

$16.6

Total firm value ($m)

$231

Total basic shares (m est)

23.1

Value per basic share ($)

$10.00

Warrants and options (12/2015, m)

2.6

Weighted average exercise price ($)

$2.07

Cash on exercise ($m)

$5.4

Total firm value ($m)

$236

Non-warrant options (12/2015, m)

1.8

Total number of shares

27.5

Diluted value per share ($)

$8.58

Source: Edison Investment Research, company reports

Financials

Quarterly and year-end update

VolitionRx released Q415 and full year results showing net losses of $2.7m for the quarter and $9.5m for the year. The majority of losses were associated with R&D costs ($1.6m and $6.1m respectively), which increased 51% for the year over 2014. The increase in R&D for the year was not surprising considering the large number of new clinical programs that were initiated by the company in 2015 (Exhibit 3). Significant clinical activity remains invested in advancing the company’s lead indication of CRC detection, but an increasing number of clinical studies have been devoted to other indications. Although the company has not provided guidance, we predict a continued increase in R&D spending in 2016 to $9.1m.

Exhibit 3: Clinical catalysts in 2016

Indication

Data

Trial description

Colorectal cancer

H216

First 2,500 samples from 14,000-person population screening study at Hvidovre Hospital complete. Will have comparison to FIT and colonoscopy.

Prostate cancer

Q216

Exploratory study at MD Anderson Cancer Center. Evaluation of NuQ for early detection of anaplastic prostate cancer vs castration-resistant prostate cancer.

Prostate cancer

Q116

Retrospective study designed to differentiate patients with aggressive prostate cancer, indolent prostate cancer, and healthy volunteers.

Prostate cancer

Q117

120-person multicenter screening study in collaboration with ImmuneHealth in Belgium to test NuQ’s ability to detect prostate cancer.

Colorectal cancer

H216

4,800-person study at Hvidovre Hospital.

Pan-cancer

H117

4,700-person study at Bonn University Hospital. Study screening for 27 of the most common solid and haematological cancers.

Lung cancer

H216

600-person study at Bonn University Hospital. Aim is to confirm pilot results of NuQ for early detection of lung cancer. Control groups of healthy and patients with non-cancerous lung disease.

Endometriosis

H216

500-person study at the University of Oxford. Laparoscopically confirmed endometriosis with healthy individuals.

Source: VolitionRx

Other costs were $1.0m and $3.9m for Q415 and the year (73% and 105% increase year-on-year, respectively), the increase in which was primarily due to increases in salaries and professional fees associated with the uplisting and offering on NYSE MKT in February 2015.

The company ended 2015 with $5.9m in cash and equivalents, which was higher than our estimate ($3.7m) due to lower than predicted operational spending in Q415, a larger than predicted portion of expenses being non-cash, an increase in warrant exercises and changes in working capital. The cash was supplemented with a $12.8m equity raise (including greenshoe) in March 2016.

Outlook

Our forecast for 2015 was close to the reported financials. The loss for 2015 of $9.5m is less than $0.4m different from our estimate ($9.9m). Therefore, changes to our projections are small. When taking the company’s recent cost efficiencies into account for our forecasts, we have reduced the net loss for 2016 by $0.44m (to $13.9m) and for 2017 and onward by approximately $2.4m (to $18.1m in 2017). We predict that the company will need an additional $50m in cash to self-market the NuQ test and reach profitability in 2021. This is a reduction from previous estimates of $120m based on the efficiencies described above and the March 2017 capital raise of $12.8m. We recognize the future financing as illustrative debt, but these capital needs could result in significant dilution if the company decides to seek funding in equity markets.

Exhibit 4: Financial summary

$'000s

2012

2013

2014

2015

2016e

2017e

Year end 31 December

IFRS

IFRS

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

 

55

0

15

0

836

2,245

Cost of Sales

0

0

0

0

(84)

(222)

Gross Profit

55

0

15

0

752

2,023

Research & Development

(2,843)

(2,504)

(4,044)

(6,102)

(9,102)

(10,012)

Sales, General & Administrative

(1,295)

(2,072)

(1,908)

(3,904)

(5,551)

(10,151)

EBITDA

 

 

(4,083)

(4,576)

(5,937)

(10,006)

(13,901)

(18,140)

Operating Profit (before GW and except.)

(4,083)

(4,576)

(5,937)

(10,006)

(13,901)

(18,140)

Intangible Amortisation

0

0

0

0

0

0

Other

0

0

0

0

0

0

Exceptionals

0

0

0

0

0

0

Operating Profit

(4,083)

(4,576)

(5,937)

(10,006)

(13,901)

(18,140)

Net Interest

0

0

0

0

30

41

Other

(39)

840

(2,320)

471

0

0

Profit Before Tax (norm)

 

 

(4,083)

(4,576)

(8,358)

(9,666)

(13,871)

(18,099)

Profit Before Tax (FRS 3)

 

 

(4,122)

(3,736)

(8,258)

(9,535)

(13,871)

(18,099)

Tax

0

0

(0)

5

(8)

0

Deferred tax

0

0

(0)

(0)

(0)

(0)

Profit After Tax (norm)

(4,083)

(4,576)

(8,358)

(9,661)

(13,879)

(18,099)

Profit After Tax (FRS 3)

(4,122)

(3,736)

(8,258)

(9,530)

(13,879)

(18,099)

Average Number of Shares Outstanding (m)

9.4

10.8

13.5

17.7

23.4

24.4

EPS - normalised ($)

 

 

(0.44)

(0.42)

(0.62)

(0.54)

(0.59)

(0.74)

EPS - FRS 3 ($)

 

 

(0.44)

(0.34)

(0.61)

(0.54)

(0.59)

(0.74)

Dividend per share ($)

0.0

0.0

0.0

0.0

0.0

0.0

BALANCE SHEET

Fixed Assets

 

 

1,522

1,065

1,097

1,489

1,331

1,211

Intangible Assets

1,430

1,002

809

705

705

705

Tangible Assets

91

63

289

784

626

506

Other

0

0

(0)

(0)

(0)

(0)

Current Assets

 

 

416

941

2,192

6,070

8,413

17,118

Stocks

0

0

0

0

4

11

Debtors

0

0

0

0

149

400

Cash

376

889

2,139

5,916

8,106

16,554

Other

39

53

53

154

154

154

Current Liabilities

 

 

(695)

(957)

(2,713)

(1,120)

(1,127)

(1,127)

Creditors

(695)

(957)

(2,713)

(1,120)

(1,127)

(1,127)

Short term borrowings

0

0

0

0

0

0

Long Term Liabilities

 

 

(635)

(433)

(352)

(548)

(548)

(25,548)

Long term borrowings

0

0

0

0

0

(25,000)

Other long term liabilities

(635)

(433)

(352)

(548)

(548)

(548)

Net Assets

 

 

607

617

224

5,891

8,069

(8,346)

CASH FLOW

Operating Cash Flow

 

 

(2,315)

(3,084)

(4,141)

(8,766)

(12,466)

(16,714)

Net Interest

0

0

0

0

0

0

Tax

0

0

0

0

0

0

Capex

(91)

(1)

(303)

(352)

(30)

(30)

Acquisitions/disposals

0

0

0

0

0

0

Financing

2,576

2,828

5,627

12,498

12,800

0

Dividends

0

0

0

0

0

0

Other

0

0

0

0

0

0

Net Cash Flow

171

(257)

1,183

3,379

304

(16,744)

Opening net debt/(cash)

 

 

(348)

(376)

(889)

(2,139)

(5,916)

(8,106)

HP finance leases initiated

0

0

0

0

0

0

Exchange rate movements

(40)

4

(44)

13

0

0

Other

-103

765

111

385

1886

191

Closing net debt/(cash)

 

 

(376)

(889)

(2,139)

(5,916)

(8,106)

8,446

Source: Company accounts, Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by VolitionRx and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

More on VolitionRx

View All

Latest from the Healthcare sector

View All Healthcare content

Opexa Therapeutics — Update 1 April 2016

Opexa Therapeutics

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free